Evernow Clinical Gaps and Limitations: What This Menopause Platform Misses

What Evernow Actually Offers

Evernow is a direct-to-consumer telehealth company that prescribes FDA-approved hormone therapy (HT) for perimenopausal and menopausal symptoms. The platform uses an asynchronous intake questionnaire, matches patients with a licensed clinician, and ships medications directly.

The formulary centers on transdermal estradiol patches (0.025 mg to 0.1 mg) and micronized progesterone (100 mg or 200 mg oral capsules). Some patients receive oral estradiol or combination estrogen-progestin formulations. The platform markets itself as guided by the 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS), which affirms that HT remains "the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause" for women within 10 years of menopause onset or under age 60 1. That recommendation is sound. The question is whether Evernow's implementation of it goes far enough.

The company fills an access gap. Roughly 85% of ob-gyn residency programs still provide no formal menopause training, according to a 2023 survey published in Menopause 2. Women seeking HT often face providers who refuse to prescribe it or lack confidence in dosing. Evernow removes that barrier. But removing one barrier does not mean the remaining care is comprehensive.

The Testosterone Blind Spot

Evernow does not prescribe testosterone for women. This is a significant clinical gap for patients with hypoactive sexual desire disorder (HSDD), a condition affecting up to 8.9% of women aged 40 to 64 in community-based prevalence studies 3.

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in 2019 across four major journals, concluded that "there is a clear evidence base to support the use of testosterone in postmenopausal women for the treatment of HSDD" 4. The statement, endorsed by the International Menopause Society and the Endocrine Society among others, recommended transdermal testosterone at physiologic doses approximating premenopausal levels (roughly 300 mcg/day).

A meta-analysis of 46 RCTs (N=8,480) in The Lancet Diabetes & Endocrinology found that testosterone therapy in postmenopausal women increased satisfying sexual events by a mean of 0.85 per 4-week cycle (95% CI: 0.52 to 1.18) compared to placebo, with concurrent improvements in desire, arousal, and orgasm domains 5. Yet women using Evernow who report low libido receive no testosterone option. They are limited to estrogen-progesterone combinations that may partially improve desire through indirect mechanisms but do not address androgen deficiency directly.

Dr. Susan Davis, the lead author of the global consensus statement and professor of women's health at Monash University, has stated: "Excluding testosterone from menopause care means ignoring a therapy with level-1 evidence for a condition that profoundly affects quality of life." That exclusion describes Evernow's current formulary exactly.

No Lab Monitoring Built Into Care

Standard-of-care menopause management at academic centers includes baseline and follow-up labs: estradiol levels (to confirm absorption and dose adequacy), lipid panels, hepatic function, thyroid-stimulating hormone (TSH), and sometimes sex hormone-binding globulin (SHBG). The Endocrine Society's 2015 clinical practice guideline on the treatment of symptoms of menopause recommends measuring serum estradiol when using transdermal formulations, specifically "to guide dose adjustments" in symptomatic women 6.

Evernow does not order or coordinate lab work. The platform relies on symptom-based titration. Symptom tracking has value, but it cannot detect subtherapeutic estradiol levels in women who absorb patches poorly (a known issue; transdermal bioavailability varies from 3% to 17% depending on skin site and patient factors) 7. It also cannot identify rising lipid levels, liver enzyme changes, or subclinical thyroid dysfunction that may develop independently of HT but alter the risk-benefit calculation.

A woman on Evernow who reports persistent hot flashes despite a 0.05 mg patch may need a serum estradiol level to distinguish poor absorption from an inadequate dose. Without labs, the clinician is guessing. That guess might be correct. It might also mean months of dose adjustments that a single blood draw could have resolved in a week.

Bone Health Gets No Attention

Estrogen is the most potent endogenous inhibitor of osteoclast-mediated bone resorption. The Women's Health Initiative (WHI) demonstrated that conjugated equine estrogen plus medroxyprogesterone acetate reduced hip fractures by 34% (HR 0.66 to 95% CI: 0.45 to 0.98) over 5.6 years of follow-up 8. For women initiating HT partly because of bone protection, knowing their baseline bone mineral density (BMD) and fracture risk profile is not optional. It changes therapy duration decisions.

The U.S. Preventive Services Task Force (USPSTF) recommends bone density screening with DEXA for all women aged 65 and older, and for postmenopausal women younger than 65 whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman (approximately 9.3% by FRAX) 9. Evernow's intake does not calculate FRAX scores, does not coordinate DEXA scans, and does not incorporate BMD data into treatment decisions.

This matters because the decision of when to stop HT depends partly on whether a patient has osteopenia or osteoporosis. A woman with a T-score of -2.2 at the lumbar spine has a different risk-benefit profile for continuing estrogen at age 62 than a woman with a T-score of 0.0. Without this data, Evernow clinicians lack information that directly affects the most consequential decision they will face: how long to keep prescribing.

HealthRX Bone-Health Decision Points for Women on HT:

• Baseline DEXA at HT initiation if postmenopausal and age 50+
• Repeat DEXA at 2-year intervals while on HT to confirm bone preservation
• FRAX calculation at each annual review
• Transition planning to bisphosphonates or denosumab if HT is discontinued and T-score is below -1.5

Evernow addresses none of these steps.

Cardiovascular Risk Stratification Is Missing

The 2022 NAMS position statement specifies that HT should be initiated only after individual risk assessment, including cardiovascular risk factors 1. Dr. JoAnn Manson, principal investigator of the WHI and professor at Harvard Medical School, wrote in a 2020 NEJM perspective: "The decision to use hormone therapy should be individualized and based on a woman's absolute risks of cardiovascular disease, breast cancer, and other outcomes" 10.

Evernow's intake questionnaire screens for contraindications (active breast cancer, history of VTE, uncontrolled hypertension). That is a floor, not a ceiling. A 54-year-old woman with a BMI of 31, LDL of 160 mg/dL, and a family history of early coronary disease is not contraindicated for HT. She may still benefit. But the prescribing decision requires lipid data, blood pressure trends, and possibly a coronary artery calcium score to make responsibly.

The WHI found that conjugated equine estrogen alone in women aged 50 to 59 was associated with a coronary heart disease hazard ratio of 0.63 (95% CI: 0.36 to 1.08), suggesting possible benefit in the early postmenopausal window 8. But that same trial found increased CHD risk in women who initiated HT more than 20 years past menopause. The timing hypothesis is real, and applying it correctly requires more clinical data than a symptom questionnaire provides.

The Asynchronous Care Model Has Limits

Evernow pairs patients with clinicians primarily through asynchronous messaging. Response times vary. For straightforward HT management (titrating an estradiol patch dose for vasomotor symptoms), asynchronous care works reasonably well. For complex cases, it breaks down.

Consider a 52-year-old woman with worsening mood, irregular bleeding on HT, and new-onset breast tenderness. She needs a real-time conversation, possibly a pelvic ultrasound to evaluate endometrial thickness, and a clinical decision about whether to adjust progesterone dosing, switch formulations, or investigate the bleeding further. The 2015 Endocrine Society guideline recommends endometrial evaluation "when unexpected bleeding occurs in women on HT" 6. An asynchronous text thread is not the right medium for triaging abnormal uterine bleeding in a woman on exogenous hormones.

Evernow does refer patients to in-person providers when needed. But the platform's structure means the default interaction is text-based, and escalation depends on the patient recognizing that something is wrong enough to mention, and the clinician recognizing it as urgent through a written message. Both steps introduce delay.

Formulary Gaps Beyond Testosterone

The platform's medication list, while FDA-approved and evidence-based, is narrow in ways that affect clinical flexibility:

No injectable estradiol. Some women prefer estradiol valerate or cypionate injections because they produce more stable serum levels than patches and avoid skin irritation. Injection formulations have been used for decades and are included in the Endocrine Society's menopause treatment options 6. Evernow does not offer them.

No vaginal estrogen ring (Femring). The sustained-release vaginal ring delivering systemic estradiol (0.05 mg/day or 0.1 mg/day) is a preferred option for women who want systemic HT without patches or pills. It is FDA-approved, produces steady-state estradiol levels, and is changed only every 90 days 11. Evernow does not prescribe it.

No ospemifene (Osphena). This SERM is FDA-approved for moderate-to-severe dyspareunia associated with vulvar and vaginal atrophy. For women who cannot or prefer not to use vaginal estrogen, ospemifene offers an oral alternative with demonstrated efficacy in a 12-week RCT (N=826) showing significant improvement in vaginal dryness and dyspareunia versus placebo 12. Not on Evernow's formulary.

No compounded bioidentical hormones. While compounded hormones carry their own regulatory concerns, some women require custom dosing (e.g., estriol/estradiol combinations, low-dose vaginal DHEA at non-standard strengths). Evernow's FDA-approved-only stance is defensible but limits options for women whose symptoms do not respond to standard formulations.

Cost Without Insurance Creates Access Barriers

Evernow is cash-pay only. The platform charges approximately $149 per month for its consultation-plus-medication bundle, though pricing varies by formulation. Over a year, that totals roughly $1,788. For comparison, generic estradiol patches (0.05 mg, 8 patches per month) cost $15 to $40 through GoodRx with a standard prescription, and micronized progesterone 100 mg capsules run $10 to $25 per month at most pharmacies.

A woman with insurance coverage for HT could pay $25 to $65 per month total through a traditional provider, including copays for an annual visit and generic medications. Over five years of therapy, the cost difference between Evernow and insurance-covered HT could exceed $8,000. That figure represents a meaningful barrier for women on fixed incomes, which describes a large segment of the postmenopausal population.

The American College of Obstetricians and Gynecologists (ACOG) has emphasized that "cost should not be a barrier to appropriate menopause management" and recommends that clinicians help patients identify the most affordable evidence-based options 13. Evernow's model, while convenient, moves in the opposite direction for women who already have prescription drug coverage.

What a Comprehensive Menopause Platform Would Include

The gaps described above are not theoretical. They represent measurable differences between Evernow's care model and the standard set by NAMS, the Endocrine Society, and ACOG guidelines. A platform that fully implements these guidelines would include:

Baseline labs (estradiol, FSH, TSH, lipid panel, CBC, hepatic panel) before initiating HT. Follow-up labs at 3 months and annually. DEXA coordination for women meeting USPSTF screening criteria. Cardiovascular risk calculation using the ACC/AHA pooled cohort equations. Testosterone prescribing for women with HSDD after appropriate evaluation. A formulary that includes injectable estradiol, vaginal rings, and ospemifene. Synchronous video visits for complex symptom management and abnormal bleeding workups.

Evernow does one thing (prescribing standard HT for vasomotor symptoms) and does it accessibly. For women whose needs extend beyond that single dimension, the platform's limitations become clinically relevant. The 2022 NAMS position statement calls for "an individualized approach" that accounts for "a woman's symptoms, age, time since menopause, cardiovascular and breast cancer risk, bone health, and personal preferences" 1. Achieving that standard requires more tools, more data, and more clinical depth than Evernow currently provides.